Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Canine Arthritis Treatment Market

Canine Arthritis Treatment Market Analysis

  • Report ID: GMI8835
  • Published Date: Apr 2024
  • Report Format: PDF

Canine Arthritis Treatment Market Analysis

The market based on treatment type is segmented into drugs, supplements, surgical procedures, and other treatment types. The drugs treatment type accounted for majority of market share of 42.3% in 2023.
 

  • Drugs offer effective relief from pain and inflammation associated with canine arthritis. Drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids have demonstrated efficacy in alleviating symptoms and improving joint function in arthritic dogs.
     
  • Further, ongoing research and development efforts have led to the introduction of new and improved drugs for treating canine arthritis. Pharmaceutical companies are investing in the development of novel drug formulations, delivery systems, and therapeutic targets to enhance the efficacy and safety of arthritis medications for dogs.
     
Canine Arthritis Treatment Market, By Arthritis Type (2023)

The canine arthritis treatment market based on arthritis type is classified into osteoarthritis, osteochondrosis, rheumatoid arthritis, and traumatic arthritis. The osteoarthritis segment is expected to reach USD 1.4 billion by 2032.
 

  • Osteoarthritis is more prevalent in older dogs, and therefore the aging pet demographic contributes to the overall increase in osteoarthritis cases. The rise in pet obesity is a significant contributor to the increase in osteoarthritis cases among canines. Excess body weight places additional strain on the joints, leading to accelerated wear and tear and an increased risk of developing osteoarthritis.
     
North America Canine Arthritis Treatment Market, 2021 – 2032 (USD Million)

North America canine arthritis treatment market accounted for USD 1 billion market revenue in 2023 and is anticipated to grow at CAGR of 4.6% between 2024 – 2032 period.
 

  • Adoption of companion animal, growing prevalence of canine arthritis, and rise in per capita animal healthcare expenditure in the region is expected to supplement the market growth. According to the American Pet Products Association's 2021-2022 National Pet Owners Survey, 54% of households in the U.S. have pet dogs. Thus, increasing number of pet owners coupled with increasing awareness regarding their proper health is projected to accelerate the regional expansion.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Canine arthritis treatment industry size was worth USD 2.4 billion in 2023 and will exhibit a 4.7% CAGR between 2024 and 2032 due to the rising incidence of arthritis and related conditions in canines.

The osteoarthritis segment in the canine arthritis treatment industry will reach USD 1.4 billion by 2032, driven by the high prevalence of osteoarthritis among dogs coupled with aging population of dogs, rise in pet obesity and advancements in veterinary medicine.

North America canine arthritis treatment market recorded USD 1 billion in 2023 and will grow at 4.6% CAGR from 2024 to 2032, attributed to the growing prevalence of canine arthritis, and rise in per capita animal healthcare expenditure in the region.

Some of the key canine arthritis treatment companies are American Regent, Inc., Bayer AG, Boehringer Ingelheim Animal Health, CEVA Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., among others.

Canine Arthritis Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 217
  • Countries covered: 22
  • Pages: 145
 Download Free Sample